PFIZER INC (PFE): M&A transaction — Pfizer completes $43B acquisition of Seagen; Seagen becomes wholly owned subsidiary

PFIZER INC

Acquisition closed Dec 14, 2023; $229 per share in cash for total enterprise value approx. $43 billion.
Adds Seagen's four approved medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) and ADC technology.
Pfizer's oncology pipeline doubled to 60 programs across multiple modalities.
To address FTC concerns, Pfizer irrevocably donated U.S. royalty rights from Bavencio (avelumab) to AACR.
Pfizer's oncology portfolio now includes over 25 approved medicines and biosimilars across >40 indications.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

PFIZER INC completed an acquisition involving Seagen Inc. for $229 in cash per share, for a total enterprise value of approximately $43 billion (closed 2023-12-14).

Action: acquisition
Counterparty: Seagen Inc.
Consideration: $229 in cash per share, for a total enterprise value of approximately $43 billion
Closing: 2023-12-14

Exact text from the filing

Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.

View on SEC.gov

95 m&a transactions filed in the last 30 days. Browse all m&a transactions →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0001193125-23-295562

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.